| abstract |
The present invention is directed to administering an effective amount of an anti-HBV biologically active 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, having the formula: A method for treating a host infected with hepatitis B virus is characterized by:n n n n n n n n Wheren n n R is H, straight, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, Is selected from the group consisting of amino acid residues, mono, di, or triphosphates, and phosphate derivatives;n n n The base is a purine or pyrimidine base which may be optionally substituted.n n n 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, alone or in another 2'-deoxy-β-L-erythro-pentofuranonucleoside Or in combination with other anti-hepatitis B agents. |